前哨淋巴结定位对子宫内膜癌分子亚组的附加预后价值
这项回顾性队列研究纳入206例子宫内膜癌患者,在瑞士伯尔尼大学医院接受包含前哨淋巴结定位的手术治疗,并对前哨淋巴结行超分期、对原发肿瘤行分子分型。结果发现前哨淋巴结宏转移在p53abn肿瘤中最常见(24.2%),且是MMRd亚组复发和疾病特异性死亡的独立预测因素,但在p53abn亚组中未见附加影响。
要点
- 前哨淋巴结宏转移在p53abn肿瘤中最常见(24.2%),其次为MMRd(13.7%)、NSMP(5.5%)和POLEmut(0%)(p = .006)。
- 前哨淋巴结宏转移与整个研究队列复发风险升高显著相关(p > .001),NSMP亚组亦然(p > .001)。
- 在MMRd亚组,前哨淋巴结宏转移是多变量Cox回归中复发(p = .030)和疾病特异性死亡(p = .047)的显著预测因素。
核心结论
- 前哨淋巴结宏转移是MMRd子宫内膜癌患者复发和疾病特异性死亡的独立预测因素。
- 在p53abn子宫内膜癌亚组中,前哨淋巴结宏转移对肿瘤学结局未见附加影响。
研究设计与样本
- 回顾性队列研究,纳入在瑞士伯尔尼大学医院接受包含前哨淋巴结定位手术治疗的子宫内膜癌患者。
- 对前哨淋巴结行超分期,并对原发肿瘤行分子分析。
- 研究队列共206例患者,其中197例肿瘤样本接受了分子分型。
主要发现
- 分子分型结果为POLEmut 11.2%、MMRd 25.9%、NSMP 46.2%、p53abn 16.8%。
- 共切除834枚前哨淋巴结。
- 前哨淋巴结宏转移在p53abn肿瘤中最常见(24.2%),其次为MMRd(13.7%)、NSMP(5.5%)和POLEmut(0%)(p = .006)。
- 平均随访时间为70.9个月。
- 前哨淋巴结宏转移与整个研究队列复发风险升高显著相关(p > .001),在NSMP亚组亦然(p > .001)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Treatment approaches for endometrial cancer became more personalized in the last decade, mainly due to two key advancements - sentinel lymph node (SLN) mapping and molecular classification. However, their prognostic interaction remains relatively unexplored. METHODS: This retrospective cohort study included patients with endometrial cancer, who underwent surgical treatment including SLN mapping at the Bern University Hospital, Switzerland. Ultrastaging of the SLNs and a molecular analysis on the primary tumor was performed. RESULTS: The study cohort included 206 patients, of which 197 tumor samples underwent molecular classification. 11.2 % were classified as POLEmut, 25.9 % as MMRd, 46.2 % as NSMP, and 16.8 % as p53abn. Overall, 834 SLN were removed. SLN macrometastasis were most prevalent in patients with p53abn tumors (24.2 %), followed by MMRd (13.7 %), NSMP (5.5 %), and POLEmut (0 %) tumors (p = .006). Mean follow-up time was 70.9 months. SLN macrometastasis was significantly associated with a higher risk of recurrence in the entire study cohort (p > .001) and the NSMP subgroup (p > .001). In the MMRd subgroup, SLN macrometastasis remained a significant predictor of recurrence (p = .030) and disease-specific death (p = .047) in multivariate Cox regression analysis. For patients with p53abn endometrial cancer, there was no association between SLN macrometastasis and risk of recurrence (p = .618) or disease specific death (p = .798). CONCLUSIONS: SLN macrometastasis is an independent predictor of recurrence and disease-specific death in patients with MMRd endometrial cancer. In the subgroup of p53abn endometrial cancers, SLN macrometastasis did not have an added impact on oncological outcome.
引用
- Siegenthaler F, Imboden S, Büchi C, et al. Added prognostic value of sentinel lymph node mapping in endometrial cancer to molecular subgroups. Gynecol Oncol. 2025. PMID: 39764854. doi:10.1016/j.ygyno.2024.12.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。